Short Interest in Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Decreases By 97.0%

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 9 shares, a drop of 97.0% from the April 30th total of 300 shares. Based on an average trading volume of 2,945 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Enzon Pharmaceuticals Stock Performance

Shares of OTCMKTS ENZN remained flat at $5.95 during midday trading on Thursday. The company’s stock had a trading volume of 735 shares, compared to its average volume of 1,181. Enzon Pharmaceuticals has a 12 month low of $1.50 and a 12 month high of $12.99. The company has a current ratio of 2.01, a quick ratio of 1.16 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average price is $6.07 and its 200-day moving average price is $5.51. The firm has a market capitalization of $4.40 million, a price-to-earnings ratio of -0.87 and a beta of -0.03.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share for the quarter. The firm had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.